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Primary Sj€ogren's syndrome (pSS) is associated with HLA-DRB1 loci, but the association of amino acid
variations in the hypervariable region of the HLA-DR b1 chain with pSS is largely unknown. In this
study, we aimed to identify the amino acid variations within the hypervariable region of HLA-DRB1
molecule which are associated with the susceptibility to pSS. We sequenced the 2nd exon of the HLA-
DRB1 locus in 52 pSS patients and 179 controls. The HLA-DRB1*0803 is the allele that shows the
strongest association with pSS in Chinese population (OR ¼ 3.0, P ¼ 2.4  104). Furthermore, amino
acid variations within the binding pocket P7 and P9 are associated with the susceptibility to pSS. An
interaction between two residues within P7, b47 and b67, is associated with pSS. Structural modeling
studies demonstrated that the electrostatics of peptide binding pocket 9 are opposite in pSS-
susceptible and -protective HLA-DRB1 alleles. In conclusion, our results suggest that structural het-
erogeneity of the HLA-DRB1 peptide binding pocket P7 and P9 might play a role in the pathogenesis
of pSS.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Primary Sj€ogren's syndrome (pSS) is an autoimmune disorder
targeting the exocrine glands and leading to mucosal and
conjunctival dryness [1]. As for most autoimmune diseases, the
HLA class II loci have been convincingly demonstrated to be
associated with the pSS [2,3]. The HLA class II alleles associated
with pSS are different among populations. For example, HLA-
DRB1*15 and HLA-DRB1*03 are associated with pSS in Cauca-
sians [4], the HLA-DRB1*11 is associated with pSS in Jewish [5],
while the HLA-DRB1*04 is associated with pSS in Japanese [6]. Inmobile).addition, a marginal, but not significant association between
HLA-DRB1*08 allele and pSS was reported in the Chinese popu-
lation [6].
Although it is convincing that HLA class II loci are associated
with pSS, themechanism of the association is largely unknown. The
HLA class II complex binds peptides via its hypervariable region
(HVR) and presents the peptide to CD4 T cells. The highly poly-
morphic HLA class II alleles differ from each other mainly in amino
acid residues within the HVR. Identification and characterization of
the HLA class II susceptibility alleles and amino acid variations
within the HVR region will help to understand the pathogenesis of
the disease.
In this study, our aim was two folds. First, we took this oppor-
tunity to identify HLA-DRB1 allele(s) associatedwith pSS in Chinese
population. Secondly, we extended this study by determining the
effect of the amino acid variations within the HVR of HLA-DRB1
molecule on pSS.
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2.1. Patients and controls
Peripheral blood samples were collected from thirty-one pSS
patients in The First Affiliated Hospital of Xiamen University. All
patients were diagnosed according to the standards defined by
criteria of the AmericaneEuropean Consensus Group in 2002 [7].
The gender- and age-matched healthy controls were recruited from
the Xiamen University Hospital. This study was approved by the
ethics committee of Xiamen University.
2.2. DNA preparation
The genomic DNA was extracted from peripheral blood
leukocytes using a TaKaRa Blood Genome DNA Extraction Kit
(Takara Biotechnology, Dalian Co., Ltd., China) according to the
manufacturer's recommendations. The amount of DNA was
measured using an UV-spectrophotometer at A260/280 nm and the
quality of DNA was checked by 0.8% agarose gel electrophoresis.
2.3. HLA-DR typing
Genotyping was performed by sequencing the 2nd exon of the
HLA-DRB1 as previously described by Kotsch et al. [8]. Briefly, the
HLA-DRB1 was amplified by 14 combinations of allele family
specific primers located in introns. PCR products were sequenced
by group-specific primers. The highly polymorphic sequence of
each individual was first analyzed by Mixed Sequence Reader
http://msr.cs.nthu.edu.tw/ [9] to distinguish two alleles sequence.
Alignment was performed using WU-BLAST http://www.ebi.ac.uk/
Tools/sss/wublast/ to define the HLA-DRB1 allele.
2.4. Meta-analysis
An exhaustive search of the Medline database was performed to
identify eligible studies. The inclusion criteria were the following:
the design should be a case-control study based on unrelated
individuals. Studies were excluded if one of the following existed:
(a) the design based on family or sibling pairs; (b) genotype
frequencies or numbers not reported. The following information
was collected from each study: author, year of publication,
description of ethnicity in the study population, HLA typing
technique, diagnosis criteria for pSS, and total number of cases.
For the control group in each study, we assessed departures
from the HardyeWeinberg equilibrium using the c2 test. The
heterogeneity across studies was evaluated using Cochran's Q-
statistics. The random effect model was used for meta-analysis
when a heterogeneity was indicated by a significant Q-statistic
(P < 0.10), otherwise the fixed effect model was used. The allele
frequencies for the DRB1 polymorphism were determined in each
study using the allele-counting method. The odds ratio (OR), 95%
confidence intervals (CI), and P values were estimated for each
study by comparing the allele frequencies. Meta-analysis was per-
formed to calculate the pooled OR, 95% CI and P values. Statistical
analysis was performed using the Comprehensive Meta-Analysis
computer program (Biosta, Englewood, NJ, USA).
2.5. Stepwise regression modeling
The stepwise (“forwards-backwards”) procedure started by
taking the best amino acids (lowest P value) into the regression
model, and iteratively adding amino acids (“forwards”) to evaluate
if the goodness-of-fit (the Akaike Information Criterion (AIC)
metric) improves. An amino acid already in the model can beejected from themodel (“backwards”) if that improves the AIC. This
procedurewas performed in R (http://www.r-project.org) using the
“glm” and “step” functions.2.6. Statistical analyses
The analyses for association between pSS and the HLA-DR
variants were performed using the c2 test. Results are expressed
as mean ± SD. The statistical significance of differences between
groups was calculated by either the chi-square test or Fisher's exact
test. Power calculations were performed by using SPSS. A P value of
<0.05 was considered significant.2.7. 3D protein structure modeling of HLA-DR molecules
Graphical representations of structures were constructed with
PyMOL 1.3 (Schr€odinger, LLC). The structural models of pSS-
susceptible and pSS-nonrelated HLA-DR molecules were
constructed based on the Protein Data Bank (PDB) ID: 4MDI [10]. All
the modeling structure was built through SWISS-MODEL server
(http://swissmodel.expasy.org/) using the deep view project.
Electrostatic surface potential was calculated by the APBS
PyMOL plugin [11], with externally generated PQR files from the
PDB2PQR website (http://nbcr-222.ucsd.edu/pdb2pqr_1.8/) [12]
and are colored from red (negative potential, 10 kT) to blue
(positive potential, þ10 kT).3. Results
3.1. Characteristics of the dataset
We analyzed fifty-two pSS patients (7 males and 45 females)
which were recruited from the First Affiliated Hospital of Xiamen
University. The mean age of the patients at the time of the study
was 44 ± 12.52 years (mean ± SD). Among the patients, 65.9% and
83.7% suffered xerophthalmia and xerostomia respectively. 66% of
the patients had the elevated IgG levels in the sera, and 86.3% and
35.3% of the patients carried anti-SSA and anti-SSB autoantibodies
respectively. 40.8% and 43.5% of the patients showed low concen-
tration of complement 3 (C3) and C4 respectively. The histopath-
ological evaluation of glandular biopsies showed a mean focus
score of 1.92± 1.56. The disease durationwas 27.91 ± 29.98months.3.2. HLA-DRB1 typing
The HLA-DRB1 typing was performed in 52 patients and 179
controls by sequencing the 2nd exon of the gene. The frequencies
of HLA-DRB1 alleles in patients and controls are presented in the
Supplementary Table 1. Three HLA-DRB1 alleles including
DRB1*0803, DRB1*1401 and DRB1*1602 were associated with
an increased risk of pSS (Table 1). The frequency of the
HLA-DRB1*0803 allele in patients (22.1%) was significantly higher
than that in controls (8.66%) (P ¼ 0.00028, OR ¼ 3.0, 95% CI:
1.66e5.41). The frequency of the HLA-DRB1*1401 was significantly
higher only in the anti-SSB positive patients (9.30%) than in
controls (3.63%) (P ¼ 0.03, OR ¼ 2.7, 95% CI: 1.09e6.79). The
frequency of the HLA-DRB1*1602 was 8.6% in patients and 3.4% in
controls (P ¼ 0.03, OR ¼ 2.7, 95% CI: 1.12e6.68). In addition, the
HLA-DRB1*1201 allele was negatively associated with pSS, with the
allele frequency of 1.0% and 6.7% in the patients and controls
respectively (P ¼ 0.05, OR ¼ 0.14, 95% CI: 0.02e1.01), suggesting a
protective role in the development of pSS.
Table 1
Association of HLA-DBR1 loci with pSS in Chinese population.
HLA-DRB1 na % OR (95% CI) P value
0803
control (n ¼ 358) 31 8.66
all patients (n ¼ 104) 23 22.12 3.00 (1.66e5.41) 2.80E-04
anti-SSAþ (n ¼ 86) 19 22.09 2.99 (1.59e5.61) 6.30E-04
anti-SSBþ (n ¼ 34) 7 20.59 2.73 (1.10e6.79) 0.03b
1401
control (n ¼ 358) 13 3.63
all patients (n ¼ 104) 8 7.69 2.21 (0.89e5.49) NS
anti-SSAþ (n ¼ 86) 8 9.3 2.72 (1.09e6.79) 0.03b
anti-SSBþ (n ¼ 34) 3 8.82 2.56 (0.69e9.50) NS
1602
control (n ¼ 358) 12 3.35
all patients (n ¼ 104) 9 8.65 2.73 (1.12e6.68) 0.03b
anti-SSAþ (n ¼ 86) 8 9.3 2.95 (1.17e7.48) 0.02b
anti-SSBþ (n ¼ 34) 2 5.88 1.80 (0.38e8.40) NS
1201
control (n ¼ 358) 24 6.7
all patients (n ¼ 104) 1 0.96 0.14(0.02e1.01) 0.05
anti-SSAþ (n ¼ 86) 1 1.16 0.16(0.02e1.01) NS
anti-SSBþ (n ¼ 34) 0 0 0.07(0.004e1.08) NS
Note:
a Number of chromosomes.
b Not significant after correction.
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We then performed a meta-analysis to confirm the novel
association between the four HLA-DRB1 allele and pSS. Since the
HLA-DRB1*1602 allele was studied only in this study, we combine
all HLA-DRB1*16 alleles for the meta-analysis. Ten case-control
studies passed the criteria relating to HLA-DRB1 polymorphisms
and susceptibility to pSS were recruited for the meta-analysis
[4,6,13e20], For the HLA-DRB1*0803 allele, 5 case-control studies
were recruited for the meta-analysis, with 492 pSS patients andFig. 1. Forest plot of case-control studies examining the association of pSS. Meta-analysis wa
(b), HLA-DRB1*1401 (c) and HLA-DRB1*1201 (d). The odds ratio (OR), 95% confidence inter
calculate the pooled OR, 95% CI and P values using the Comprehensive Meta-Analysis compu
of the individual study in the meta-analysis. The diamonds represent the OR (centre line o1860 controls. The meta-analysis showed a strong association
between the HLA-DRB1*0803 allele and pSS (P ¼ 2.79E-08,
OR ¼ 2.77, 95% CI: 1.93e3.97) (Fig. 1(A)). For the HLA-DRB1*1401
allele, the meta-analysis with 252 patients and 1120 controls did
not confirm the association between the allele and pSS (P ¼ 0.32,
OR ¼ 1.43, 95% CI: 0.70e2.90) (Fig. 1(B)). The meta-analysis with
426 patients and 1310 control showed a weak association between
the HLA-DRB1*16 allele and pSS (P ¼ 1.99E-03, OR ¼ 2.47, 95%
CI: 1.39e4.37) (Fig. 1(C)). The negative association between the
HLA-DRB1*1201 alleles and pSS was also confirmed by the
meta-analysis with 252 patients and 1120 control studies
(P ¼ 0.045, OR ¼ 0.23, 95% CI: 0.05e0.96) (Fig. 1(D)). Taken
together, the meta-analysis confirmed that the HLA-DRB1*08:03
and HLA-DRB1*16 alleles were associated with an increased risk
of pSS and the HLA-DRB1*12:01 allele was associated with a
decreased risk of the disease.
3.4. HLA-DRB1 amino acid variations in pSS patients and controls
The sequence of the 2nd exon of the HLA-DRB1 genes allowed us
to determine the amino acid variations within the HVR region of
the HLA-DRB1. Sequencing analysis of the polymorphic exon 2 of
the DRB1 gene showed 27 polymorphic amino acid positions.
Among them, 8 polymorphisms are biallelic and remaining 19
positions accommodate more than two amino acid variants. Sig-
nificant differences in the frequencies of amino acids between pSS
patients and controls were observed at 9 of the 27 polymorphic
amino acids, at positions 13, 26, 31, 37, 47, 57, 70, 71 and 74,
(Table 2). Of these, three amino acid positions were associated with
an increased risk to pSS, including Gly13 (P ¼ 0.005, OR ¼ 1.91, 95%
CI: 1.20e3.05), Ser57 (P ¼ 0.003, OR ¼ 2.18, 95% CI: 1.30e3.65) and
Leu74 (P ¼ 0.0001, OR ¼ 2.89, 95% CI: 1.65e5.06). Two amino acids
of Tyr26 (P ¼ 0.009, OR ¼ 0.35, 95% CI: 0.16e0.79) and Ile31
(P ¼ 0.038, OR ¼ 0.24, 95% CI: 0.06e1.03) were associated with as performed examining the association of pSS with HLA-DRB1*0803 (a), HLA-DRB1*16
vals (CI), and P values were estimated for each study. Meta-analysis was performed to
ter program (Biosta, Englewood, NJ, USA). The size of the square represents the weight
f the diamond) and 95% CI (lateral tips of the diamond) of the meta-analysis.
Table 2









OR (95% Cl) P value
13 F 4 (3.8) 27 (7.5) 0.49 (0.17e1.43)
G 40 (38.5) 88 (24.6) 1.92 (1.21e3.05) 5.37E-03
H 10 (9.6) 47 (13.1) 0.7 (0.34e1.45)
R 18 (17.3) 56 (15.6) 1.13 (0.63e2.02)
S 28 (26.9) 122 (34.1) 0.71 (0.44e1.16)
Y 4 (3.8) 18 (5) 0.76 (0.25e2.28)
26 F 83 (79.8) 241 (67.3) 1.92 (1.13e3.25)
L 14 (13.5) 56 (15.6) 0.84 (0.45e1.58)
Y 7 (6.7) 61 (17) 0.35 (0.16e0.79) 9.00E-03
31 F 100 (96.1) 329 (91.9) 2.2 (0.76e6.42)
I 2 (1.9) 27 (7.5) 0.24 (0.06e1.03) 0.04
V 2(1.9) 2(0.6) 3.49(0.49e25.08)
37 F 17(16.3) 40(11.2) 1.55(0.84e2.87)
L 12(11.5) 50(14) 0.8 (0.41e1.57)
N 8 (7.7) 83 (23.2) 0.28 (0.13e0.59) 4.71E-04
S 20 (19.2) 68 (19) 1.02 (0.58e1.77)
Y 47 (45.2) 117 (32.7) 1.7 (1.09e2.65) 0.02
47 F 37 (35.6) 180 (50.2) 0.55 (0.35e0.86) 8.67E-03
Y 67 (64.4) 178 (49.7) 1.83 (1.17e2.88) 8.67E-03
57 A 9 (8.7) 18 (5) 1.79 (0.78e4.11)
D 49 (47.1) 197 (55) 0.73 (0.47e1.13)
S 29 (27.9) 54 (15.1) 2.18 (1.30e3.65) 2.76E-03
V 17 (16.3) 89 (24.9) 0.59 (0.33e1.05)
70 D 64 (61.5) 173 (48.3) 1.71 (1.10e2.67) 0.02
Q 24 (23) 137 (38.3) 0.48 (0.29e0.80) 4.21E-03
R 16 (15.4) 48 (13.4) 1.17 (0.64e2.17)
71 A 9 (8.7) 42 (11.7) 0.71 (0.33e1.52)
E 1 (0.9) 11 (3.1) 0.31 (0.04e2.40)
K 5 (4.8) 52 (14.5) 0.3 (0.12e0.76) 7.99E-03
R 89 (85.6) 253 (70.7) 2.46 (1.36e4.45) 2.27E-03
74 A 52 (50) 199 (55.6) 0.8 (0.52e1.24)
E 17 (16.3) 66 (18.4) 0.86 (0.48e1.55)
L 26 (25) 37 (10.3) 2.89 (1.65e5.06) 1.25E-04
Q 4 (3.8) 19 (5.3) 0.71 (0.24e2.15)
R 5 (4.8) 37 (10.3) 0.44 (0.17e1.15) 0.08
pSS ¼ Primary Sj€ogren's syndrome; OR ¼ Odds Ratio; 95% CI ¼ 95% confidence
interval.P values in the associated amino acids were calculated with the
CochraneArmitage test. Only P values that were significant are shown.
a Number of chromosomes.
Fig. 2. Associations of amino acid variations within HLA-DRB1 hypervariable region
with pSS. The numbers indicate the position of the amino acid residue. The colors
denote the MHC II binding pockets of amino acids, where P1 stands for pocket 1 and et.
(For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article.)
R. Huang et al. / Journal of Autoimmunity 57 (2015) 53e5956decreased risk to pSS. The other four positions at 37, 47, 70 and 71
showed discordant associations, where Tyr37 (P ¼ 0.02, OR ¼ 1.70,
95% CI: 1.09e2.65), Tyr47 (P ¼ 0.009, OR ¼ 1.83, 95% CI: 1.17e2.88),
Asp70 (P ¼ 0.02, OR ¼ 1.70, 95% CI: 1.10e2.67) and Arg71 (P ¼ 0.002,
OR ¼ 2.46, 95% CI:1.36e4.45) were associated with an increased
risk to pSS, however, Asn37 (P ¼ 0.0004, OR ¼ 0.28, 95% CI:
0.13e0.59), Phe47 (P ¼ 0.009, OR ¼ 0.55, 95% CI: 0.35e0.86), Gln70
(P ¼ 0.004, OR ¼ 0.48, 95% CI: 0.29e0.80) and Lys71 (P ¼ 0.008,
OR¼ 0.30, 95% CI: 0.12e0.76) were associated with a decreased risk
of the disease.
All of those amino acids are located in MHC-II peptide binding
pockets 4, 7 and 9 (Fig. 2), Suggesting these three binding pockets
are important for pSS susceptibility.3.5. Stepwise generalized linear regression analysis to determine
causative amino acids
To determine whether the association of amino acid with pSS
is due to its own contribution or due to its linkage with other
amino acid, we performed a stepwise regression analysis by R
software [21]. Since the regression analysis included all nine po-
sitions would cause quasi-complete separation problem [22], we
performed the regression analysis for two subset of amino acids.
One included risk positions (13, 57, and 74) and both risk and
protective positions (37, 47, 70, and 71). Another included pro-
tective positions (26, 31) and both risk and protective positions(37, 47, 70, and 71). The regression analysis showed an indepen-
dent effect for five amino acids at position of Gly-13 (omnibus
P ¼ 0.05), Asn-37 (omnibus P ¼ 0.02), Val-57 (omnibus P ¼ 0.02),
Ile-67(omnibus P ¼ 0.01) and Glu-70 (omnibus P ¼ 0.01). There-
fore, our analysis for independent effects demonstrated that these
five positions gave the main contributions to association with pSS,
whereas the other five amino acid positions might associated only
by linkage disequilibrium.3.6. Effect of the interaction between two amino acids within
peptide binding pocket 7
Interestingly, in contrast toHLA-DRB1*0803andHLA-DRB1*1601,
the HLA-DRB1*0802 and HLA-DRB1*1602 were not associated with
pSS. HLA-DRB1*0803 differs from HLA-DRB1*0802 at the amino
acid position 57 and 67, while HLA-DRB1*1602 differs from
HLA-DRB1*1601 only at the position 67 (Fig. 3), indicating that the
amino acid at the position 67 might contribute to the difference in
association. However, individual amino acid analysis demonstrated
that the amino acid at position 67 alonewas not associated with the
diseases.
Residue 67 of the HLA-DR b-chain is located in pocket 7, together
with residues 65 and 69 of the a-chain and residues 28, 30, 47, 61,
70 of the b-chain [23].We hypothesized that the position b67might
contribute to the diseases by interacting with other P7 residues. We
then evaluated the effect of interaction between position 67 and
other positions within the P7 on pSS. The interaction between
position of b47 and b67 showed an effect on the risk to pSS. Position
47 is dipolymorphism with Tyr or Phe, while Ile, Leu and Phe are
presented at position 67. Since both Ile and Leu are aliphatic and of
similar size [24], we combined these two amino acids as one group,
denoted as (I þ L)67. There are four combination of amino acids at
the position 47 and 67, including Y47 with (I þ L)67, Y47 with F67, F47
with (Iþ L)67, and F47 with F67 (Table 3). Among them, combination
of Y47 with (I þ L)67 was associated with an increased risk of pSS
(P ¼ 0.001, OR ¼ 2.07, 95% CI: 1.33e3.23), while the combination of
Y47 with F67 was not. The combination of F47 with (I þ L)67 was
associated with a decrease risk of pSS (P¼ 0.001, OR¼ 0.39, 95% CI:
0.22e0.68), but the combination of F47 with F67 was not. Taken
together, these results suggest that the interaction of the two amino
acids at MHC II binding pocket 7 is associated with pSS.
Interestingly, the combination of Y47(I þ L)67 is presented all
three risk HLA-DRB1 alleles including *0803, *1401 and *1602 in
Fig. 3. Residues that differ among HLA-DRB1 alleles that are positively or negatively associated with pSS. Amino acid that identical to 0802 are shown as “-” with the exception of
position b47 and b67. Risk residues at position 47 and 67 are in red color, whereas protective residues are in green.
R. Huang et al. / Journal of Autoimmunity 57 (2015) 53e59 57this study, whereas the combination of F47(Iþ L)67 is presented in
the disease-protection associated allele HLA-DRB1*1201 (Fig. 3).
3.7. pSS susceptibility correlates with electrostatic charge
differences in the P9 pockets of DRB1*0802, DRB1*0803
and DRB1*1201
Although HLA-DRB1*0803 differs from HLA-DRB1*0802 in two
residues, previous studies showed the structure of them are
different [25]. To compare the three-dimensional structure of pSS-
non-related (HLA-DRB1*0802), pSS-susceptible (HLA-DRB1*0803)
and pSS-resistant (HLA-DRB1*1201) alleles, we performed homol-
ogy modeling to explore the effect of these key residues on the
HLA-DR molecule (Fig. 4).
We further characterized the electrostatic potential on the sur-
face of the HLA-DRB1 molecules. The HLA-DRB1*0802 subtype,
which is not associated with pSS, has a negative electrostatics
potential in pocket 9 (Fig. 4(A)). The risk allele HLA-DRB1*08:03 has
a nearly neutral electrostatics potential in pocket 9 (Fig. 4(B)), while
the protective allele HLA-DRB1*12:01 has a positive electrostatics
potential in pocket 9 (Fig. 4(C)). These results showed that differ-
ence in the electrostatic potential of pocket 9 might confer different
effects of HLA-DRB1*08:02, *08:03 and *12:01 on pSS risks.
4. Discussion
In this current study, we investigated the association between
HLA-DRB1 loci and pSS in the Chinese population. Our results
demonstrated that HLA-DRB1*0803 and *1602 were associated
with the increased risk of pSS and the HLA-DRB1*1201 was
associated with a decreased risk of disease. These associations wereTable 3





OR (95% CI) P value
Y I þ L 0.6 0.42 2.07 (1.33e3.23) 1.33E-03
Y F 0.05 0.08 0.57 (0.22e1.52) NS
F I þ L 0.16 0.34 0.39 (0.22e0.68) 9.91E-04
F F 0.19 0.17 1.18 (0.67e2.07) NS
Note: b47 and b67 denote the amino acid position on DRB1 b chain, which located in
peptide binding pocket 7; pSS ¼ Primary Sj€ogren's syndrome; OR¼ Odds Ratio; 95%
CI ¼ 95% confidence interval. P values in the associated amino acids were calculated
with the c2 test.further confirmed using meta-analysis. In this case-control study,
no association was observed between pSS and the HLA-DBR1*03,
*04, *11 or *15 which were associated with pSS in other
populations [5,6,14,20]. This result supports that the HLA class II
alleles associated with pSS are different among populations.
HLA-DRB1*0803 is the allele shows strongest association with
pSS in Chinese population, while it is not associated with the
disease in Caucasian and in Jewish [5,6]. This discrepancy might
due to the diversity in the frequency of the HLA-DRB1*0803
among populations, where it in south Asia is rather high
(approximately 10%) while it is nearly absent in Caucasian and in
Jewish [6,26].
HLA-DRB1*0803 and *0802 differ only in two amino acid
positions, b47 (Phe in *0802, Tyr in *0803) in the P7 pocket and b57
(Asp in *0802, Ser in *0803) in the P9 pocket. Therefore, the two
amino acid residues might play an essential role in the suscepti-
bility to pSS.
This (Tyr/Phe 47) polymorphism is known to be important for
peptide binding and presentation to T cells [27]. Unlike the very
similar Phenylalanine, Tyrosine contains a reactive hydroxyl group,
this difference would might affect the selectivity of the binding of
pathogenic peptides to the HLA-DR pocket and thus might increase
the risk for developing pSS by altering MHC-TCR peptide binding
and presentation to T cells.
Our findings show an interaction between positions 47 and 67
within the P7 pocket is associated with pSS. The P7 pocket is
deeper and with polarity amino acid Tyr47 in pSS-susceptible
HLA-DRB1*0803 (47-Tyr and 67I or 67L) than in the pSS-resistant
HLA-DRB1*1201 (47-Phe and 67-Phe) [25], suggesting that the
size of pocket 7 might be important to pSS susceptibility.
Our three-dimensional modeling results shows that variation in
pSS associated residues encoded by HLA-DRB1 impose distinct
electrostatics characteristics on the HLA-DR peptide binding groove
pocket 9. HLA-DR binding pocket electrostatics potential is critical
for autoimmune disease susceptible. For example, RA susceptibility
correlates with electrostatic charge differences in the P4 pockets of
DRB1*0401 and DRB1*0402 [10]. It is also well established that the
HLA-DQ b57 in pocket 9 has a strong influence over the shape of the
peptide binding groove at this point. HLA-DQb57 Asp gives rise to a
closed groove whilst HLA-DQ b57 Ala or Ser is more ‘relaxed’ [28].
These differences have a major impact on the types of peptides that
are presented. One example is in T1D, the amino acid residue at
position 57 of the DQb chain plays a key role in the genetic
susceptibility to disease [29]. Our structure modeling results
showed a distinct pocket 9 electrostatics potential in pSS-risk and
Fig. 4. Structure models of pSS-susceptible and resistant HLA/DRB1 molecules, (A) pSS unrelated HLA-DRB1*0802. (B) pSS-susceptible HLA-DRB1*0803. (C) pSS-protective HLA-
DRB1*1201. Electrostatic potential maps have been calculated separately for these three molecule. A significant difference was found in P7 pocket and P9 pocket. P7 pocket in pSS-
susceptible HLA-DRB1*0802 is narrow with a steeper cleft (arrow) in A, whereas wider and deeper in *0803 with a slope cleft (arrow) in B. P9 pocket has a negative electrostatics
potential (red) in 0802, nearly neutral in 0803 and positive in 1201 (blue).
R. Huang et al. / Journal of Autoimmunity 57 (2015) 53e5958resistant allele, which might has an effect on autoimmune peptide
presentation.
In summary, we have identified MHC class II pocket amino acid
signatures that impose distinct structural and physiochemical
characteristics on the HLA-DRB1 peptide binding groove and confer
significant risk for pSS. The findings are highly relevant for and
important to evaluate in future experimental studies of antigen
presentation in pSS.
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